AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01288066 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemiarthroplasty
Description: Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
Study NCT01288066 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total arthroplasty
Description: Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
Study NCT04413396 — intervention group
Intervention type: PROCEDURE
Intervention: Outpatient Parenteral Antibiotic Therapy
Description: Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
Study NCT03935100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping
Description: Endoscopic clips fired to close mucosa over diverticular defects.
Study NCT03935100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - colonoscopy without clipping
Description: Colonoscopy performed, no clipping of diverticula
Study NCT01087190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Description: isoniazid 300 mg po qd for 9 months
Study NCT02893514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening Only (SO) condition
Description: Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
Study NCT02893514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUSIT Condition
Description: Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
Study NCT02990910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Individualized opioid analgesia
Description: (a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
Study NCT02990910 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: conventional opioid analgesia
Description: (b) all received 25μg/kg morphine
Study NCT00695487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 9-d-tetra hydro cannabinol
Description: 0.125mg/kg iv one time
Study NCT00695487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC 9-d-tetra hydro cannabinol
Description: 0.125mg/kg iv one time
Study NCT01991210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
Study NCT01991210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
Study NCT00657527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00657527 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cholesterol lowering diet
Study NCT01563302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-STAT3Rx
Description: Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
Study NCT00635596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT110
Description: MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
Study NCT01397084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole 20 mg
Description: esomeprazole 20 mg once daily for 8 weeks
Study NCT01993147 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dual task paradigm pilot
Study NCT01654341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, dietary and educational program
Study NCT03410550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Training
Description: Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
Study NCT04670848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepiz One+ vs. polysomnography
Description: Simultaneous sleep recording with polysomnography and Sleepiz One+ device
Study NCT01576263 — intervention group
Intervention type: DRUG
Intervention: Autologous blood transfusion with ropivacaine
Description: Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
Study NCT02345629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain/Symptom Questionnaire
Description: Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
Study NCT01576263 — intervention group
Intervention type: DRUG
Intervention: Autologous blood transfusion with ropivacaine
Description: Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
Study NCT04617509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A GS-248
Description: Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study NCT04617509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Formulation A GS-248
Description: Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study NCT04617509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formulation B GS-248
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study NCT04617509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Formulation B GS-248
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study NCT00331682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00331682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00232232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study NCT04531800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor
Description: In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
Study NCT04531800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-concentrated growth factor
Description: In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
Study NCT03176888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-exertion, high-intensity interval training (REHIT)
Description: As in arm/group description
Study NCT03176888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
Study NCT05170620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation
Description: Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
Study NCT00687219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Administered at 1.0 µg/kg/week SC for 48 weeks
Study NCT00687219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and \<14g/dL; treatment duration is 48 weeks
Study NCT01852006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
Study NCT00618072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin and rosiglitazone
Description: 4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
Study NCT00618072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and rosiglitazone
Description: 4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
Study NCT01975753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT01975753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT04229082 — intervention group
Intervention type: OTHER
Intervention: observational
Study NCT04048876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: oral
Study NCT04048876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01578525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical Care Service
Description: Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
Study NCT01975753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT04479423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soda-water instead of pure water to observe gastric filling
Description: All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
Study NCT03087669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®
Description: Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
Study NCT03087669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP intervention using Noradrenalin
Description: At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
Study NCT00333814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 350 µg; injection drug delivery system at Day 0
Study NCT00333814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone 700 µg injection drug delivery system at Day 0
Study NCT00333814 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection at Day 0
Study NCT02330471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spray
Description: surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
Study NCT02330471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forced
Description: surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
Study NCT03267576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
Study NCT03267576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
Study NCT03267576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin at a stable dose of >= 1500 mg/day throughout the study including the washout period between each intervention.
Study NCT01247012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Omegaven 1g/kg/day until infant receiving full enteral feeds
Study NCT01247012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid minimization
Description: 1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)
Study NCT03607292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior sciatic nerve block
Description: A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
Study NCT03607292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior sciatic nerve block
Description: Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
Study NCT00542425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 µg subcutaneous daily
Study NCT00542425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous daily
Study NCT02901249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study NCT05466084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue Glue for mesh fixation
Description: one arm of the study had their mesh fixed with tissue glue applied at multiple sites
Study NCT05466084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metallic Tackers for mesh fixation
Description: in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
Study NCT03770741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modify cardio-respiratory support to avoid cerebral hypoxia
Description: modification of cardio-respiratory support based on an evidence-based treatment guideline
Study NCT03770741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Monitoring and treatment according to local guidelines and practice
Study NCT01631487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 10 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
Study NCT01631487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 25 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
Study NCT01631487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 50 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
Study NCT01631487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.
Study NCT02368093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Description: 120mg per day with once daily dose taken after breakfast for 6 months
Study NCT01846962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
Study NCT01846962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
Study NCT01846962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: six-foods elimination diet
Description: six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
Study NCT01846962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Viscous Budesonide (OVB)
Description: The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
Study NCT04393597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fasted)
Description: Subjects take single dose of DWJ1458 on a fated condition
Study NCT04393597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fed)
Description: Subjects take single dose of DWJ1458 after high-fat diet
Study NCT00913887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
Study NCT00913887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
Study NCT00913887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
Study NCT02443246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)
Study NCT02443246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00361231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Study NCT00361231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Study NCT00361231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Study NCT01668446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil tablets(50 mg) daily
Study NCT01668446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerat
Study NCT03158740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DII-Based Counseling System
Description: DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.